Expression profiles of ADAMs and clinical significance of ADAM-28 in colorectal carcinoma

WANG Jinmeng; ZHU Li; WANG Jingying; LI Wenfeng; XU Yunsheng

doi:10.3969/j.issn.1009-0460.2017.08.008

Abstract：Objective To investigate the expression profiles of a disintegrin and metalloproteinases(ADAMs) family menbers ADAM-8,ADAM-9,ADAM-10,ADAM-12,ADAM-15,ADAM-17,ADAM-19,ADAM-28,ADAM-33 in colorectal carcinoma and to determine the clinical significance of ADAM-28 in colorectal carcinoma.Methods QPCR was used to detect the relative levels of ADAMs mRNA in colorectal carcinoma and matched non-cancerous tissues,and Western blotting was used to detected ADAM-28 protein expression.Immunohistochemistry was taken to analyze the expression of ADAM-28 in 218 colorectal carcinoma samples and its correlation with clinicopathological variables was then analyzed.Results The mRNAs expression of ADAM-8,ADAM-9,ADAM-17,ADAM-28 and ADAM-33 were up-regulated in colorectal carcinoma,ADAM-12 mRNA was down-regulated,and while the mRNAs of ADAM-10,ADAM-15 and ADAM-19 had no obvious changes.ADAM-28 protein was up-regulated in colorectal carcinoma.Immunohistochemistry showed that the positive rate of ADAM-28 in colorectal carcinoma tissues was 68.8％ (150/218).The expression of ADAM-28 significantly correlated with regional lymph node metastasis,differentiation and TNM stage(P＜0.05).Survival analysis revealed that patients with positive ADAM-28 expression had a shorter median overall survival than those of ADAM-28 negative expression (36.75 months vs.95.10 months,P＜0.001).Cox multi-factors analysis showed that ADAM-28 was an independent factor influencing overall survival (P＜0.05).Conclusion ADAM-28 contributes to the occurrence and development of colorectal carcinoma;ADAM-28 may be served as a potential biomarker in predicting patients' outcome.